You are here

Immunovant

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses

Clinical Trials Arena

Mon, 09/9/24 - 11:16 am

Graves' disease

monoclonal antibodies

clinical trials

Immunovant stakes claim for FcRn niche, posting midphase Graves’ data and plotting next steps

Fierce Biotech

Thu, 12/21/23 - 09:46 am

clinical trials

Graves' disease

Immunovant shares surge as early antibody treatment data beats expectations

Yahoo/Reuters

Tue, 09/26/23 - 11:43 am

clinical trials

autoimmune diseases

Immunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 Study

Marketwatch

Tue, 05/23/23 - 10:12 am

autoimmune disease

Immunovant flashes the data that made Roivant want to reacquire it at a potentially hefty premium

Endpoints

Tue, 06/1/21 - 10:53 pm

myasthenia gravis

thyroid eye disease

Immatics takes up the SPAC baton

EP Vantage

Wed, 03/17/21 - 11:27 pm

The SPAC story departs from the script

EP Vantage

Wed, 03/10/21 - 10:42 am

Immunovant stock loses half its value after pausing dosing in trial of thyroid eye disease treatment

Marketwatch

Tue, 02/2/21 - 10:42 am

thyroid eye disease

clinical trials

Following the pack, Immunovant rushes into pivotal studies

EP Vantage

Wed, 08/26/20 - 11:00 am

clinical trials

myasthenia gravis

Important catalysts approach for smaller biotechs

EP Vantage

Wed, 06/24/20 - 10:35 am

Turning Point Therapeutics

Intra-Cellular Therapies

clinical trials

Newly-public Immunovant announces first proof-of-concept success

Endpoints

Mon, 03/30/20 - 10:38 am

thyroid eye disease

clinical trials

One less rival for Immunovant, as Alexion abandons FcRn inhibitor

Endpoints

Wed, 02/26/20 - 10:36 am

Immunovant set to land on Nasdaq via HSAC merger

Fierce Biotech

Wed, 10/2/19 - 10:56 am

Health Sciences Acquisitions Corporation